Maurizio Scaltriti

Also affiliated with AstraZeneca (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

(2023)10.1158/1078-0432.c.6533080.v1

Top 100%

0DataRank

Top 100%0 citations

Dexter X. Jin, Ruchita Rathod, Jeffrey S. Ross, Lewis C. Cantley, Maurizio Scaltriti +6 more

Papers

Driven by 26 papers — median percentile 0. Top paper: “Clusterin (SGP‐2, ApoJ) expression is downregulated in low‐ and high‐grade human prostate cancer”.

Clusterin (SGP‐2, ApoJ) expression is downregulated in low‐ and high‐grade human prostate cancer

International Journal of Cancer(2003)10.1002/ijc.11496

N/A

4.5DataRank · unranked

99 citations

Maurizio Brausi, Andrea Amorosi, Andrea Caporali, Domenico D'Arca, Serenella Astancolle +5 more

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3953

N/A

3.2DataRank · unranked

108 citations

Kenji Tamura, Mafalda Oliveira, Eva Ciruelos, Ingrid A. Mayer, Marie‐Paule Sablin +23 more

FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

Cancer Cell(2020)10.1016/j.ccell.2020.08.003

N/A

0.742DataRank · unranked

140 citations

Jesper L.V. Mååg, Srushti Kittane, Yanyan Cai, Wouter R. Karthaus, Erik Ladewig +22 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Nature Communications(2022)10.1038/s41467-022-32828-6

N/A

0.721DataRank · unranked

121 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors

Cell Death and Disease(2021)10.1038/s41419-021-03457-6

N/A

0.457DataRank · unranked

20 citations

Sheeba Jacob, Richard Kurupi, Carter K. Fairchild, Bin Hu, Madhavi Puchalapalli +6 more

Pancreatoblastomas and mixed and pure acinar cell carcinomas share epigenetic signatures distinct from other neoplasms of the pancreas

Modern Pathology(2021)10.1038/s41379-021-00989-2

N/A

0.450DataRank · unranked

11 citations

Monika Vyas, Atsushi Tanaka, Lu Wang, Armita Bahrami, Kerem Özcan +11 more

Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3324

N/A

0DataRank · unranked

41 citations

Marta Palafox, Laia Monserrat, Fara Brasó‐Maristany, Andreu Òdena, Mònica Sánchez-Guixé +26 more

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2657

N/A

0DataRank · unranked

39 citations

Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk +16 more

Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients

Annals of Oncology(2020)10.1016/j.annonc.2020.04.008

N/A

0DataRank · unranked

33 citations

Bo Liu, Alison M. Schram, Pedram Razavi, Stephen M. Lagana, Y. Zhang +10 more

Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns

Genome Medicine(2020)10.1186/s13073-020-00774-x

N/A

0DataRank · unranked

23 citations

Miquel Duran‐Frigola, Albert Gris‐Oliver, Marta Palafox, Maurizio Scaltriti, Pedram Razavi +6 more

UDP-glucose pyrophosphorylase 2, a regulator of glycosylation and glycogen, is essential for pancreatic cancer growth

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.13.337998

N/A

0DataRank · unranked

0 citations

Qingwen Zhou, Eneda Toska, Jacqueline Galeas, Angel A. Ku, Richard P. Koche +6 more

UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth

Proceedings of the National Academy of Sciences(2021)10.1073/pnas.2103592118

N/A

0DataRank · unranked

56 citations

Qingwen Zhou, Eneda Toska, Jacqueline Galeas, Angel A. Ku, Richard P. Koche +6 more

Genomic Alterations in PIK3CA -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors

Cancer Research(2021)10.1158/0008-5472.can-20-3232

N/A

0DataRank · unranked

35 citations

Guotai Xu, Fan Wu, Flavia Michelini, Carmen Chan, Xuan Qu +16 more

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies

npj Breast Cancer(2021)10.1038/s41523-021-00334-5

N/A

0DataRank · unranked

15 citations

Pier Selenica, Yingjie Zhu, Helen Won, Michael F. Berger, Lorenzo Ferrando +9 more

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Research Square(2021)10.21203/rs.3.rs-236645/v1

N/A

0DataRank · unranked

12 citations

Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel González-Pérez, Mafalda Oliveira +33 more

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.08.22.457244

N/A

0DataRank · unranked

2 citations

Jonathan Zorea, Sankar Jagadeeshan, Avital Beeri Shnerb, Jebrane Bouaoud, Lucas Michon +24 more

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications(2022)10.1038/s41467-022-28848-x

N/A

0DataRank · unranked

114 citations

Helen Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong +27 more

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Journal for ImmunoTherapy of Cancer(2022)10.1136/jitc-2021-003917

N/A

0DataRank · unranked

70 citations

Jonathan Zorea, Sankar Jagadeeshan, Avital Beeri Shnerb, Sooraj Mathukkada, Jebrane Bouaoud +27 more

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2270

N/A

0DataRank · unranked

30 citations

Dexter X. Jin, Ruchita Rathod, Jeffrey S. Ross, Lewis C. Cantley, Maurizio Scaltriti +6 more

Data from Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2023)10.1158/0008-5472.c.6497889

N/A

0DataRank · unranked

0 citations

Magüi Gili, Maurizio Scaltriti, Violeta Serra, Marta Guzmán, Wouter Nijkamp +6 more

Data from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

(2023)10.1158/1078-0432.c.6533080.v1

Top 100%

0DataRank

Top 100%0 citations

Dexter X. Jin, Ruchita Rathod, Jeffrey S. Ross, Lewis C. Cantley, Maurizio Scaltriti +6 more

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0215

N/A

0DataRank · unranked

293 citations

Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai +44 more

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0571

N/A

0DataRank · unranked

70 citations

Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen Won, Sophie Shifman +29 more

Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts

Nature Communications(2020)10.1038/s41467-020-15885-7

N/A

0DataRank · unranked

58 citations

Wenhuo Hu, François Audenet, Nima Almassi, Aphrothiti J. Hanrahan, Katie S. Murray +32 more

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer

Cancer Cell(2020)10.1016/j.ccell.2020.08.016

N/A

0DataRank · unranked

54 citations

Alan J. Wright, Paula D’Santos, De‐En Hu, Richard L. Hesketh, Yaniv Lubling +19 more

Phase and context shape the function of composite oncogenic mutations

Nature(2020)10.1038/s41586-020-2315-8

N/A

0DataRank · unranked

47 citations

Francisco J. Sánchez‐Rivera, Yanyan Cai, Craig M. Bielski, Evan Biederstedt, Philip Jonsson +13 more

Maurizio Scaltriti

Indexed papers

Top data-sharing exemplar

Papers